## Viral Hepatitis Training and Treatment Update Streaming Webinar

Program Agenda

| 8:10 am  8:15 am  Viral Hepatitis, Discovery of HCV and its Natural History  • The evolving epidemiology of viral hepatitis around the world • Manifestations of HCV and it relationship to HIV  Hepatitis C: Update on Diagnostics • Screening and diagnostic approaches by cohort • Liver biopsy and newer, non-invasive diagnostic tools Hepatitis C: Update on Treatment • 2019 AASLD/IDSA Guidelines • Simplified Guidance  10:20 am  Break/Product Theatre I  Viral Hepatitis Update from AASLD • Worldwide perspective on Hepatitis and promising research studies • Real world outcome studies on DAA's  Case Studies 1 and 2 – Infections in Correctional Facilities; HIV/HCV Co-infection Case Studies 1 and 2 – Infections in persons who inject drugs; HCV and Decompensated Cirrhosis  Hepatitis A: What Clinicians Need to Know • The resurgence of Hep A • Risk factors and complications Recent outbreaks and the efficacy of vaccination  22:00pm  DAY 2  Beginning A: Studies Comments  Hepatitis B: Epidemiology, Natural History and Testing • The epidemiology of the Hepatitis B infection • Efficacies and opportunities in HBV testing and vaccination • The growing relationship between HBV and HDV  Anti-viral Therapies for HBV • Early detection and treatment approaches • Treating HCC in patients with Hepatitis B Reactivation of Chronic HBV • Agents to guard against the reactivation of Hepatitis B Reactivation guidelines for AALD and AGA  10:30am  Break/Product Theatre II  Delta Hepatitis and Hepatitis E: Symptoms, Diagnosis and Future Treatment • Understanding the origins and future of the newest viral hepatitis strain • Emerging diagnositic and treatment approaches • Emerging diagnositic and treatment approaches • Emerging diagnositic and treatment approaches  | DAY 1    | All Times PACIFIC Standard Time                                   |
|--|----------|---|
| 8:15 am  Viral Hepatitis, Discovery of HCV and its Natural History  The evolving epidemiology of viral hepatitis around the world  Mamifestations of HCV and it relationship to HIV  Hepatitis C: Update on Diagnostics Screening and diagnostic approaches by cohort Liver biopsy and newer, non-invasive diagnostic tools Hepatitis C: Update on Treatment 2019 AASLD/IDSA Guidelines Simplified Guidance  Nordlewide perspective on Hepatitis and promising research studies Real world outcome studies on DAA's Case Studies 1 and 2 – Infections in Correctional Facilities; HIV/HCV Co-infection Case Studies 1 and 2 – Infections in Correctional Facilities; HIV/HCV Co-infection Case Studies 1 and 2 – Infections in Correctional Facilities; HIV/HCV Co-infection Case Studies 1 and 2 – Infections in Correctional Facilities; HIV/HCV Co-infection Case Studies 3 and 4 – Infections in Correctional Facilities; HIV/HCV Co-infection Case Studies 3 and 4 – Infections in Correctional Facilities; HIV/HCV Co-infection Case Studies 3 and 4 – Infections in Correctional Facilities; HIV/HCV Co-infection Case Studies 3 and 4 – Infections in Correctional Facilities; HIV/HCV Co-infection Case Studies 3 and 4 – Infections in Correctional Facilities; HIV/HCV Co-infection Case Studies 3 and 4 – Infections in Correctional Facilities; HIV/HCV Co-infection Case Studies 3 and 4 – Infections in Correctional Facilities; HIV/HCV Co-infection Case Studies 3 and 4 – Infections in Correctional Facilities; HIV/HCV Co-infection Case Studies 3 and 4 – Infections in Correctional Facilities; HIV/HCV Co-infection Case Studies 3 and 4 – Infections in Corrections in Correction | 8:00 am  |   |
| Manifestations of HCV and it relationship to HIV Hepatitis C: Update on Diagnostics Serening and diagnostic approaches by cohort Liver biopsy and newer, non-invasive diagnostic tools Hepatitis C: Update on Treatment 2019 AASLD/IDSA Guidelines Simplified Guidance  10:20 am Break/Product Theatre I  Viral Hepatitis Update from AASLD Worldwide perspective on Hepatitis and promising research studies Real world outcome studies on DAA's Case Studies 1 and 2 – Infections in Correctional Facilities; HIV/HCV Co-infection Case Studies 3 and 4 – Infections in persons who inject drugs; HCV and Decompensated Cirrhosis Hepatitis A: What Clinicians Need to Know The resurgence of Hep A Risk factors and complications Recent outbreaks and the efficacy of vaccination  12:00pm  DAY 2 Bray A Hepatitis B: Epidemiology, Natural History and Testing The epidemiology of the Hepatitis B infection Fificacies and opportunities in HBV testing and vaccination The growing relationship between HBV and HDV  Anti-viral Therapies for HBV The rating HCC in patients with Hepatitis B Guidance statements for co-infected patients  Reactivation of Chronic HBV Agents to guard against the reactivation of Hepatitis B Reactivation of Offorious HBV Hepatitis and Hepatitis E: Symptoms, Diagnosis and Future Treatment Understanding the origins and future of the newest viral hepatitis strain Emerging diagnostic and treatment approaches  Closing Comments and Post Test  |          | Viral Hepatitis, Discovery of HCV and Its Natural History         |
| Hepatitis C: Update on Diagnostics   |          |   |
| 9:00 am 9:00 am 9:00 am 10:20 am 10:20 am 10:20 am  Break/Product Theatre I  Viral Hepatitis Update from AASLD  • Worldwide perspective on Hepatitis and promising research studies • Real world outcome studies on DAA's • Reas Studies 3 and 4 – Infections in Correctional Facilities; HIV/HCV Co-infection Case Studies 3 and 4 – Infections in Correctional Facilities; HIV/HCV and Decompensated Cirrhosis Hepatitis A: What Clinicians Need to Know • The resurgence of Hep A • Risk factors and complications Recent outbreaks and the efficacy of vaccination  12:00pm  12:00pm  Bummary and Closing Comments  Hepatitis B: Epidemiology, Natural History and Testing • The epidemiology of the Hepatitis B infection • Efficacies and opportunities in HBV testing and vaccination • The growing relationship between HBV and HDV  Anti-viral Therapies for HBV • Early detection and treatment approaches • Treating HCC in patients with Hepatitis B • Guidance statements for co-infected patients  Reactivation of Chronic HBV • Agents to guard against the reactivation of Hepatitis B Reactivation guidelines for AALD and AGA  10:30am  Break/Product Theatre II  Delta Hepatitis and Hepatitis E: Symptoms, Diagnosis and Future Treatment • Understanding the origins and future of the newest viral hepatitis strain • Emerging diagnostic and treatment approaches   |          | Manifestations of HCV and it relationship to HIV                  |
| 9:00 am  P9:00 am  Pepatitis C: Update on Treatment 2019 AASLD/IDSA Guidelines Simplified Guidance  10:20 am  Break/Product Theatre I  Viral Hepatitis Update from AASLD  Worldwide perspective on Hepatitis and promising research studies Real world outcome studies on DAA's Case Studies I and 2 – Infections in Correctional Facilities; HIV/HCV Co-infection Case Studies 3 and 4 – Infections in Persons who inject drugs; HCV and Decompensated Cirrhosis  Hepatitis A: What Clinicians Need to Know  The resurgence of Hep A Risk factors and complications Recent outbreaks and the efficacy of vaccination  12:00pm  Summary and Closing Comments  Hepatitis B: Epidemiology, Natural History and Testing The epidemiology of the Hepatitis B infection Efficacies and opportunities in HBV testing and vaccination  Efficacies and opportunities in HBV testing and vaccination  The growing relationship between HBV and HDV  Anti-viral Therapies for HBV Early detection and treatment approaches Treating HCC in patients with Hepatitis B Guidance statements for co-infected patients  Reactivation of Chronic HBV Agents to guard against the reactivation of Hepatitis B Reactivation guidelines for AALD and AGA  10:30am  Break/Product Theatre II  Delta Hepatitis and Hepatitis E: Symptoms, Diagnosis and Future Treatment Understanding the origins and future of the newest viral hepatitis strain Emerging diagnostic and treatment approaches  Emerging diagnostic and treatment approaches   | 9:00 am  |   |
| Hepatitis C: Update on Treatment  • 2019 AASLD/IDSA Guidelines • Simplified Guidance  10:20 am  Break/Product Theatre I  Viral Hepatitis Update from AASLD  • Worldwide perspective on Hepatitis and promising research studies • Real world outcome studies on DAA's  Case Studies 1 and 2 – Infections in Correctional Facilities; HIV/HCV Co-infection Case Studies 3 and 4 – Infections in persons who inject drugs; HCV and Decompensated Cirrhosis  Hepatitis A: What Clinicians Need to Know  • The resurgence of Hep A • Risk factors and complications Recent outbreaks and the efficacy of vaccination  12:00pm  Summary and Closing Comments  Hepatitis B: Epidemiology, Natural History and Testing • The epidemiology of the Hepatitis B infection • Efficacies and opportunities in HBV testing and vaccination • The growing relationship between HBV and HDV  Anti-viral Therapies for HBV • Early detection and treatment approaches • Treating HCC in patients with Hepatitis B • Guidance statements for co-infected patients  Reactivation of Chronic HBV • Agents to guard against the reactivation of Hepatitis B Reactivation guidelines for AALD and AGA  10:30am  Break/Product Theatre II  Delta Hepatitis and Hepatitis E: Symptoms, Diagnosis and Future Treatment • Understanding the origins and future of the newest viral hepatitis strain • Emerging diagnostic and treatment approaches  Closing Comments and Post Test  |          |   |
| Hepatitis C: Update on Ireatment   |          |   |
| Simplified Guidance  Break/Product Theatre I  Viral Hepatitis Update from AASLD  • Worldwide perspective on Hepatitis and promising research studies  • Real world outcome studies on DAA's  Case Studies 1 and 2 – Infections in Correctional Facilities; HIV/HCV Co-infection Case Studies 3 and 4 – Infections in persons who inject drugs; HCV and Decompensated Cirrhosis  Hepatitis A: What Clinicians Need to Know  • The resurgence of Hep A  • Risk factors and complications Recent outbreaks and the efficacy of vaccination  12:00pm  Bummary and Closing Comments  Hepatitis B: Epidemiology, Natural History and Testing  • The epidemiology of the Hepatitis B infection • Efficacies and opportunities in HBV testing and vaccination • The growing relationship between HBV and HDV  Anti-viral Therapies for HBV  • Early detection and treatment approaches • Treating HCC in patients with Hepatitis B • Guidance statements for co-infected patients  Reactivation of Chronic HBV • Agents to guard against the reactivation of Hepatitis B Reactivation guidelines for AALD and AGA  10:30am  Break/Product Theatre II  Delta Hepatitis and Hepatitis E: Symptoms, Diagnosis and Future Treatment • Understanding the origins and future of the newest viral hepatitis strain • Emerging diagnostic and treatment approaches  Closing Comments and Post Test   |          |   |
| 10:20 am   Break/Product Theatre I   |          |   |
| Viral Hepatitis Update from AASLD  Worldwide perspective on Hepatitis and promising research studies Real world outcome studies on DAA's Case Studies 1 and 2 – Infections in Correctional Facilities; HIV/HCV Co-infection Case Studies 3 and 4 – Infections in persons who inject drugs; HCV and Decompensated Cirrhosis  Hepatitis A: What Clinicians Need to Know  Repatitis A: What Clinicians Need to Know  Recent outbreaks and complications Recent outbreaks and the efficacy of vaccination  12:00pm  Summary and Closing Comments  Hepatitis B: Epidemiology, Natural History and Testing The epidemiology of the Hepatitis B infection Efficacies and opportunities in HBV testing and vaccination Efficacies and opportunities in HBV and HDV  Anti-viral Therapies for HBV Early detection and treatment approaches Treating HCC in patients with Hepatitis B Guidance statements for co-infected patients  Reactivation of Chronic HBV Agents to guard against the reactivation of Hepatitis B Reactivation guidelines for AALD and AGA  Break/Product Theatre II  Delta Hepatitis and Hepatitis E: Symptoms, Diagnosis and Future Treatment Emerging diagnostic and treatment approaches Emerging diagnostic and treatment approaches Emerging diagnostic and treatment approaches  Closing Comments and Post Test   |          | Simplified Guidance   |
| • Worldwide perspective on Hepatitis and promising research studies     • Real world outcome studies on DAA's     Case Studies 1 and 2 - Infections in Correctional Facilities; HIV/HCV Co-infection     Case Studies 3 and 4 - Infections in persons who inject drugs; HCV and Decompensated Cirrhosis  Hepatitis A: What Clinicians Need to Know     • The resurgence of Hep A     • Risk factors and complications     Recent outbreaks and the efficacy of vaccination  12:00pm  Summary and Closing Comments  Hepatitis B: Epidemiology, Natural History and Testing     • The epidemiology of the Hepatitis B infection     • Efficacies and opportunities in HBV testing and vaccination     • The growing relationship between HBV and HDV  Anti-viral Therapies for HBV     • Early detection and treatment approaches     • Treating HCC in patients with Hepatitis B     • Guidance statements for co-infected patients  Reactivation of Chronic HBV     • Agents to guard against the reactivation of Hepatitis B     Reactivation guidelines for AALD and AGA  10:30am  Break/Product Theatre II  Delta Hepatitis and Hepatitis E: Symptoms, Diagnosis and Future Treatment     • Understanding the origins and future of the newest viral hepatitis strain     • Emerging diagnostic and treatment approaches  Closing Comments and Post Test  | 10:20 am | Break/Product Theatre I   |
| • Real world outcome studies on DAA's  Case Studies 1 and 2 – Infections in Correctional Facilities; HIV/HCV Co-infection  Case Studies 3 and 4 – Infections in persons who inject drugs; HCV and Decompensated Cirrhosis  Hepatitis A: What Clinicians Need to Know  • The resurgence of Hep A • Risk factors and complications  Recent outbreaks and the efficacy of vaccination  12:00pm  Summary and Closing Comments  Hepatitis B: Epidemiology, Natural History and Testing • The epidemiology of the Hepatitis B infection • Efficacies and opportunities in HBV testing and vaccination • The growing relationship between HBV and HDV  Anti-viral Therapies for HBV • Early detection and treatment approaches • Treating HCC in patients with Hepatitis B • Guidance statements for co-infected patients  Reactivation of Chronic HBV • Agents to guard against the reactivation of Hepatitis B  Reactivation guidelines for AALD and AGA  10:30am  Break/Product Theatre II  Delta Hepatitis and Hepatitis E: Symptoms, Diagnosis and Future Treatment • Understanding the origins and future of the newest viral hepatitis strain • Emerging diagnostic and treatment approaches  11:45am  Closing Comments and Post Test  | 10:50 am | Viral Hepatitis Update from AASLD                                 |
| Case Studies 1 and 2 – Infections in Correctional Facilities; HIV/HCV Co-infection Case Studies 3 and 4– Infections in persons who inject drugs; HCV and Decompensated Cirrhosis  Hepatitis A: What Clinicians Need to Know  • The resurgence of Hep A • Risk factors and complications Recent outbreaks and the efficacy of vaccination  12:00pm  Summary and Closing Comments  Hepatitis B: Epidemiology, Natural History and Testing • The epidemiology of the Hepatitis B infection • Efficacies and opportunities in HBV testing and vaccination • The growing relationship between HBV and HDV  Anti-viral Therapies for HBV • Early detection and treatment approaches • Treating HCC in patients with Hepatitis B • Guidance statements for co-infected patients  Reactivation of Chronic HBV • Agents to guard against the reactivation of Hepatitis B Reactivation guidelines for AALD and AGA  10:30am  Break/Product Theatre II  Delta Hepatitis and Hepatitis E: Symptoms, Diagnosis and Future Treatment • Understanding the origins and future of the newest viral hepatitis strain • Emerging diagnostic and treatment approaches  11:45am  Closing Comments and Post Test   |          | Worldwide perspective on Hepatitis and promising research studies |
| Case Studies 3 and 4 – Infections in persons who inject drugs; HCV and Decompensated Cirrhosis  Hepatitis A: What Clinicians Need to Know  • The resurgence of Hep A • Risk factors and complications Recent outbreaks and the efficacy of vaccination  12:00pm Summary and Closing Comments  Hepatitis B: Epidemiology, Natural History and Testing • The epidemiology of the Hepatitis B infection • Efficacies and opportunities in HBV testing and vaccination • The growing relationship between HBV and HDV  Anti-viral Therapies for HBV • Early detection and treatment approaches • Treating HCC in patients with Hepatitis B • Guidance statements for co-infected patients  Reactivation of Chronic HBV  9:30am Reactivation of Chronic HBV  10:30am Break/Product Theatre II  Delta Hepatitis and Hepatitis E: Symptoms, Diagnosis and Future Treatment • Understanding the origins and future of the newest viral hepatitis strain • Emerging diagnostic and treatment approaches   |          |   |
| Hepatitis A: What Clinicians Need to Know   The resurgence of Hep A   Risk factors and complications   Recent outbreaks and the efficacy of vaccination   12:00pm   Summary and Closing Comments    DAY 2  |          |   |
| • The resurgence of Hep A • Risk factors and complications Recent outbreaks and the efficacy of vaccination  12:00pm  Summary and Closing Comments  Hepatitis B: Epidemiology, Natural History and Testing • The epidemiology of the Hepatitis B infection • Efficacies and opportunities in HBV testing and vaccination • The growing relationship between HBV and HDV  Anti-viral Therapies for HBV • Early detection and treatment approaches • Treating HCC in patients with Hepatitis B • Guidance statements for co-infected patients  Reactivation of Chronic HBV • Agents to guard against the reactivation of Hepatitis B Reactivation guidelines for AALD and AGA  10:30am  Break/Product Theatre II  Delta Hepatitis and Hepatitis E: Symptoms, Diagnosis and Future Treatment • Understanding the origins and future of the newest viral hepatitis strain • Emerging diagnostic and treatment approaches  11:45am  Closing Comments and Post Test  |          |   |
| Risk factors and complications Recent outbreaks and the efficacy of vaccination  12:00pm Summary and Closing Comments  Hepatitis B: Epidemiology, Natural History and Testing  The epidemiology of the Hepatitis B infection Efficacies and opportunities in HBV testing and vaccination The growing relationship between HBV and HDV  Anti-viral Therapies for HBV Early detection and treatment approaches Treating HCC in patients with Hepatitis B Guidance statements for co-infected patients  Reactivation of Chronic HBV Agents to guard against the reactivation of Hepatitis B Reactivation guidelines for AALD and AGA  10:30am Break/Product Theatre II  Delta Hepatitis and Hepatitis E: Symptoms, Diagnosis and Future Treatment Understanding the origins and future of the newest viral hepatitis strain Emerging diagnostic and treatment approaches  Closing Comments and Post Test  | 11:30 am |   |
| Recent outbreaks and the efficacy of vaccination   |          |   |
| 12:00pm Summary and Closing Comments  Hepatitis B: Epidemiology, Natural History and Testing  • The epidemiology of the Hepatitis B infection  • Efficacies and opportunities in HBV testing and vaccination  • The growing relationship between HBV and HDV  Anti-viral Therapies for HBV  • Early detection and treatment approaches  • Treating HCC in patients with Hepatitis B  • Guidance statements for co-infected patients  Reactivation of Chronic HBV  • Agents to guard against the reactivation of Hepatitis B  Reactivation guidelines for AALD and AGA  10:30am Break/Product Theatre II  Delta Hepatitis and Hepatitis E: Symptoms, Diagnosis and Future Treatment  • Understanding the origins and future of the newest viral hepatitis strain  • Emerging diagnostic and treatment approaches  |          |   |
| DAY 2  Hepatitis B: Epidemiology, Natural History and Testing  The epidemiology of the Hepatitis B infection  Efficacies and opportunities in HBV testing and vaccination  The growing relationship between HBV and HDV  Anti-viral Therapies for HBV  Early detection and treatment approaches  Treating HCC in patients with Hepatitis B  Guidance statements for co-infected patients  Reactivation of Chronic HBV  Agents to guard against the reactivation of Hepatitis B  Reactivation guidelines for AALD and AGA  Break/Product Theatre II  Delta Hepatitis and Hepatitis E: Symptoms, Diagnosis and Future Treatment  Understanding the origins and future of the newest viral hepatitis strain  Emerging diagnostic and treatment approaches  Closing Comments and Post Test   |          | Recent outbreaks and the efficacy of vaccination                  |
| 8:00am  • The epidemiology of the Hepatitis B infection • Efficacies and opportunities in HBV testing and vaccination • The growing relationship between HBV and HDV  Anti-viral Therapies for HBV • Early detection and treatment approaches • Treating HCC in patients with Hepatitis B • Guidance statements for co-infected patients  Reactivation of Chronic HBV • Agents to guard against the reactivation of Hepatitis B Reactivation guidelines for AALD and AGA  10:30am  Break/Product Theatre II  Delta Hepatitis and Hepatitis E: Symptoms, Diagnosis and Future Treatment • Understanding the origins and future of the newest viral hepatitis strain • Emerging diagnostic and treatment approaches  11:45am  Closing Comments and Post Test   | 12:00pm  | Summary and Closing Comments                                      |
| 8:00am  • The epidemiology of the Hepatitis B infection • Efficacies and opportunities in HBV testing and vaccination • The growing relationship between HBV and HDV  Anti-viral Therapies for HBV • Early detection and treatment approaches • Treating HCC in patients with Hepatitis B • Guidance statements for co-infected patients  Reactivation of Chronic HBV • Agents to guard against the reactivation of Hepatitis B Reactivation guidelines for AALD and AGA  10:30am  Break/Product Theatre II  Delta Hepatitis and Hepatitis E: Symptoms, Diagnosis and Future Treatment • Understanding the origins and future of the newest viral hepatitis strain • Emerging diagnostic and treatment approaches  11:45am  Closing Comments and Post Test   | DAY 2    | Hepatitis B: Epidemiology, Natural History and Testing            |
| Efficacies and opportunities in HBV testing and vaccination     The growing relationship between HBV and HDV  Anti-viral Therapies for HBV     Early detection and treatment approaches     Treating HCC in patients with Hepatitis B     Guidance statements for co-infected patients  Reactivation of Chronic HBV     Agents to guard against the reactivation of Hepatitis B Reactivation guidelines for AALD and AGA  10:30am  Break/Product Theatre II  Delta Hepatitis and Hepatitis E: Symptoms, Diagnosis and Future Treatment     Understanding the origins and future of the newest viral hepatitis strain     Emerging diagnostic and treatment approaches  11:45am  Closing Comments and Post Test   |          |   |
| Anti-viral Therapies for HBV  Early detection and treatment approaches Treating HCC in patients with Hepatitis B Guidance statements for co-infected patients  Reactivation of Chronic HBV  Agents to guard against the reactivation of Hepatitis B Reactivation guidelines for AALD and AGA  10:30am  Break/Product Theatre II  Delta Hepatitis and Hepatitis E: Symptoms, Diagnosis and Future Treatment Understanding the origins and future of the newest viral hepatitis strain Emerging diagnostic and treatment approaches  Closing Comments and Post Test  | 8:00am   |   |
| Early detection and treatment approaches     Treating HCC in patients with Hepatitis B     Guidance statements for co-infected patients      Reactivation of Chronic HBV     Agents to guard against the reactivation of Hepatitis B     Reactivation guidelines for AALD and AGA  10:30am Break/Product Theatre II  Delta Hepatitis and Hepatitis E: Symptoms, Diagnosis and Future Treatment     Understanding the origins and future of the newest viral hepatitis strain     Emerging diagnostic and treatment approaches  11:45am Closing Comments and Post Test  |          | The growing relationship between HBV and HDV                      |
| • Treating HCC in patients with Hepatitis B • Guidance statements for co-infected patients  Reactivation of Chronic HBV • Agents to guard against the reactivation of Hepatitis B Reactivation guidelines for AALD and AGA  10:30am Break/Product Theatre II  Delta Hepatitis and Hepatitis E: Symptoms, Diagnosis and Future Treatment • Understanding the origins and future of the newest viral hepatitis strain • Emerging diagnostic and treatment approaches  11:45am Closing Comments and Post Test   | 8:35am   | Anti-viral Therapies for HBV                                      |
| <ul> <li>Treating HCC in patients with Hepatitis B</li> <li>Guidance statements for co-infected patients</li> <li>Reactivation of Chronic HBV</li> <li>Agents to guard against the reactivation of Hepatitis B         Reactivation guidelines for AALD and AGA</li> <li>10:30am Break/Product Theatre II</li> <li>Delta Hepatitis and Hepatitis E: Symptoms, Diagnosis and Future Treatment         <ul> <li>Understanding the origins and future of the newest viral hepatitis strain</li> <li>Emerging diagnostic and treatment approaches</li> </ul> </li> <li>11:45am Closing Comments and Post Test</li> </ul>   |          | Early detection and treatment approaches                          |
| 9:30am   • Agents to guard against the reactivation of Hepatitis B Reactivation guidelines for AALD and AGA  10:30am   Break/Product Theatre II  Delta Hepatitis and Hepatitis E: Symptoms, Diagnosis and Future Treatment  • Understanding the origins and future of the newest viral hepatitis strain  • Emerging diagnostic and treatment approaches  11:45am   Closing Comments and Post Test  |          | Treating HCC in patients with Hepatitis B                         |
| 9:30am  • Agents to guard against the reactivation of Hepatitis B Reactivation guidelines for AALD and AGA  10:30am  Break/Product Theatre II  Delta Hepatitis and Hepatitis E: Symptoms, Diagnosis and Future Treatment  • Understanding the origins and future of the newest viral hepatitis strain  • Emerging diagnostic and treatment approaches  11:45am  Closing Comments and Post Test   |          |   |
| 10:30am Break/Product Theatre II  Delta Hepatitis and Hepatitis E: Symptoms, Diagnosis and Future Treatment  • Understanding the origins and future of the newest viral hepatitis strain • Emerging diagnostic and treatment approaches  11:45am Closing Comments and Post Test  | 9:30am   |   |
| 10:30am Break/Product Theatre II  Delta Hepatitis and Hepatitis E: Symptoms, Diagnosis and Future Treatment  • Understanding the origins and future of the newest viral hepatitis strain  • Emerging diagnostic and treatment approaches  11:45am Closing Comments and Post Test   |          |   |
| 11:00am  Delta Hepatitis and Hepatitis E: Symptoms, Diagnosis and Future Treatment  Understanding the origins and future of the newest viral hepatitis strain  Emerging diagnostic and treatment approaches  Closing Comments and Post Test  |          | Reactivation guidelines for AALD and AGA                          |
| <ul> <li>Understanding the origins and future of the newest viral hepatitis strain</li> <li>Emerging diagnostic and treatment approaches</li> <li>Closing Comments and Post Test</li> </ul>  | 10:30am  | Break/Product Theatre II  |
| • Emerging diagnostic and treatment approaches  11:45am Closing Comments and Post Test   | 11:00am  |   |
| Emerging diagnostic and treatment approaches  11:45am Closing Comments and Post Test   |          |   |
|  |          | Emerging diagnostic and treatment approaches                      |
| 12:00pm Adjourn  | 11:45am  | Closing Comments and Post Test                                    |
|  | 12:00pm  | Adjourn   |

Course Directors: Paul J. Pockros, MD - Scripps Clinic

Catherine Frenette, MD – Scripps Center for Cell and Organ Transplantation